IMCR Q4 2025 Earnings Call Summary

Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Net Revenue: $400 million from KIMTRAK in 2025, a 29% increase year-over-year.
Operating Loss: Reduced in 2025 as revenue growth outpaced operating expenses.
Cash Position: Strong balance sheet with approximately $864 million in cash and marketable securities, up over $40 million from the previous year.
Growth Rate: Sequential quarterly revenue growth has been in the range of 4% to 7%, with expectations for moderation in 2026.

2. Strategic Updates and Business Highlights

KIMTRAK Performance: Approved in 39 countries and launched in 30 markets, with a mean duration of therapy of 14 months. The drug has significantly improved survival rates for uveal melanoma patients.
Pipeline Expansion: Ongoing Phase 3 trials include:
- TEBE-AM: In second-line cutaneous melanoma, enrollment expected to complete in 2026.
- ATOM: In adjuvant uveal melanoma, with U.S. site activations planned for 2026.
- PRISM-MEL-301: In first-line cutaneous melanoma, targeting enrollment completion in 2027.
Infectious Disease and Autoimmunity: Progress in HIV and hepatitis B programs, with a CTA submitted for a type 1 diabetes candidate expected to enter Phase 1 in 2026.

3. Forward Guidance and Outlook

2026 Expectations: Anticipated growth moderation for KIMTRAK due to market saturation, with a focus on continued penetration in the U.S. and global expansion.
R&D Investments: Modest increases in R&D expenses expected as the company continues to advance its pipeline, particularly in Phase 3 trials.
Market Positioning: KIMTRAK is positioned as the standard of care in its current indications, with potential for expansion into cutaneous melanoma.

4. Bad News, Challenges, or Points of Concern

Growth Deceleration: Despite strong historical growth, the company expects revenue growth to moderate as it enters the fifth year on the market.
Competitive Landscape: Potential competition from new therapies in the melanoma space, particularly those targeting HLA-positive patients.
Enrollment Distribution: Majority of enrollment for TEBE-AM is in Europe, with only 10-15% expected from the U.S., which may impact control arm dynamics.

5. Notable Q&A Insights

TEBE-AM Enrollment: Majority from Europe, with concerns about the control arm's treatment mix impacting overall survival assumptions.
Pricing Strategy: Confidence in maintaining pricing for KIMTRAK in new indications, contingent on positive trial data.
HIV Program: Ongoing dose escalation with expectations to identify optimal dosing by year-end.
Autoimmune Programs: Early indicators of success will be critical before advancing to larger Phase 2 studies.

Overall, Immunocore Holdings demonstrated strong financial performance and strategic execution in 2025, with a robust pipeline and significant growth potential, albeit tempered by anticipated market challenges and competitive pressures.

IMCR — Immunocore Holdings plc